DanCann Pharma is a Danish pharmaceutical company focused on the discovery, development, manufacture and commercialization of medical cannabis and cannabinoid-based pharmaceuticals. The company manufactures and distributes prescription and over-the-counter pharmaceuticals, primarily focused on pain patients for the treatment of chronic diseases and pain conditions. DanCann Pharma was founded in 2018 and is headquartered in Denmark.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| JEQ Capital AB | 10,42 | 10,42 | 2024-11-25 |
| Niklas Estensson | 4,20 | 4,20 | 2024-11-25 |
| Robert Burén | 4,20 | 4,20 | 2024-11-25 |
| Alexander Schoeneck | 3,83 | 3,83 | 2024-11-25 |
| Erik Lundin | 3,15 | 3,15 | 2024-11-25 |
| Johan Alexander Kangas | 2,52 | 2,52 | 2024-11-25 |
| Love Carlsson | 2,52 | 2,52 | 2024-11-25 |
| Nils Berg | 2,52 | 2,52 | 2024-11-25 |
| Martin Linde med bolag | 2,10 | 2,10 | 2024-11-25 |
| Östen Carlssson | 2,10 | 2,10 | 2024-11-25 |
2025-10-21 Extra bolagsstämma 2025
2025-10-27 Delårsrapport 2025-Q3